Pliant shares spike on exploratory study results of lead drug in chronic liver disease

Lei Lei Wu

News Reporter

Pliant Therapeutics shared early-stage biomarker and imaging results, suggesting that patients with a chronic liver disease who received its drug had improved liver function compared …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pliant shares spike on exploratory study results of lead drug in chronic liver disease

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Biotech VC firm outlines plans for $100M fund

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Breaking down silos with a new quantitative approach to drug development

Pli­ant shares spike on ex­plorato­ry study re­sults of lead drug in chron­ic liv­er dis­ease

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Pliant shares spike on exploratory study results of lead drug in chronic liver disease